middle.news
Dimerix Prepares Blinded Review to Validate Key Kidney Trial Assumptions
8:40am on Monday 16th of March, 2026 AEDT
•
Healthcare
Read Story
Dimerix Prepares Blinded Review to Validate Key Kidney Trial Assumptions
8:40am on Monday 16th of March, 2026 AEDT
Key Points
Blinded review scheduled for late March 2026 to confirm statistical assumptions
ACTION3 Phase 3 study previously cleared futility and safety reviews
Primary endpoint focuses on proteinuria reduction, accepted by FDA
Results of blinded review expected in April 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE